Rituraj Upadhyay, Joshua D Palmer, Brett G Klamer, Haley K Perlow, Jonathan E Schoenhals, Jayeeta Ghose, Prajwal Rajappa, Dukagjin M Blakaj, Sasha Beyer, John C Grecula, Austin J Sim, Lanchun Lu, Wesley Zoller, James B Elder, Arnab Chakravarti, Evan Thomas, Raju R Raval
BACKGROUND: Current standard of care treatment for patients with ≥15 brain metastases (BM) is whole brain radiation therapy (WBRT), despite poor neurocognitive outcomes. We analyzed our institutional experience of treating these patients with stereotactic radiosurgery (SRS), with the aim of evaluating safety, cognitive outcomes, and survival metrics. METHODS: Patients who received SRS for ≥15 BMs in 1 to 5 fractions from 2014 to 2022 were included...
July 2024: Advances in Radiation Oncology